Community/Retail

Officials with the FDA noted that patients are sometimes being treated with medications that are not approved (including compounded medicines as well as hydromorphone, bupivacaine, fentanyl and clonidine) for use with an intrathecal implanted pump.

The AMA and CDC are working with their local offices, affiliates, and partners to promote and activate the campaign in their communities, with evidence-based materials to aid physicians and other health care providers in the screening, diagnosis and treatment process.

Millions worldwide dread the onset of debilitating migraines. There is a new drug class on the horizon that is thought to put a stop to the root of migraines.

The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.

In this clip, Debra Goff, PharmD, FCCP, infectious disease clinical pharmacist and Associate Professor at The Ohio State University, tells Pharmacy Times about One Health, a movement dedicated to bringing together different fields that handle antibiotics to prevent the misuse of these bacteria-killing drugs.

New research underscores the value of review by an ID physician, nurse, or pharmacist before starting OPAT.

The recently launched tool allows patients to efficiently manage their program in real-time.

A new report published in the CDC Morbidity and Mortality Weekly Report (MMWR) has linked cases of acute hepatitis A virus (HAV) infections from certain states to person-to-person transmission from drug use or homelessness.

On Wednesday, October 24, and Saturday, October 27, student pharmacists from the University of Maryland School of Pharmacy chapter of the APhA-ASP joined forces with the University of Maryland, Baltimore Police and the Drug Enforcement Administration (DEA) to host our bi-annual Drug Take-Back Day at the University’s SMC Campus Center.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

In this clip, Ruth O'Regan, MD discussed the future of chemotherapy as it relates to treating patients with breast cancer.

As targeted therapies for cancer continue to shape the health care landscape, health care providers may increasingly utilize liquid biopsies to identify potential treatment resistance.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

Site-specific immune inflammation has been examined using intralesional injections of oncolytic viruses.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The action will increase access to diagnostic tools for healthcare providers who may not have otherwise been equipped to perform tests.

In this clip, Maurie Markman, MD, discusses ovarian cancer as a chronic illness, and an increasing need for precision medicine.

Former New York Giants Running Back Tiki Barber this week delivered the keynote address at the 36th Annual CFS, presented by Physicans' Education Resource, and discussed his mother's breast cancer journey.

In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for UB’s patient safety organization Empire State Patient Safety Assurance Network, discusses the role of RTU products in pharmacy.

In this clip, Maurie Markman, who spoke at the CFS Symposium in NY this week, discussed the role of pharmacists in managing patients with cancer.

Skin cancer remains the most common form of cancer in the United States, with more than 65,000 cases of melanoma estimated in 2011, according to the CDC.

In this video, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for UB’s patient safety organization Empire State Patient Safety Assurance Network, discusses the use of RTUs in patients with cancer.

In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for University at Buffalo's patient safety organization Empire State Patient Safety Assurance Network, explains the challenges pharmacists will face in transitioning to USP800.

In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for University at Buffalo's patient safety organization Empire State Patient Safety Assurance Network, explains the challenges compounding pharmacies will face with USP800.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

As a first-year student pharmacist, I was initially overwhelmed by the number of student organizations and opportunities to get involved.

Chronic liver disease and cirrhosis can contribute to the development of liver cancer, which affects approximately 33,000 individuals in the United States each year.